Trialynx wins DPHARM Idol Disrupt for real-time trial model

Trialynx won the top prize at DPHARM Idol Disrupt 2026 in Boston for its hub-and-spoke digital model that turns clinical trial decisions into a single source of truth. The win comes as regulators and sponsors push toward real-time trials and as the company reports faster protocol drafting and fewer revision cycles across 56 studies.

Why it matters: - Trialynx is pitching a digital workflow for clinical research that could reduce delays caused by document-by-document trial planning. - The approach aligns with the FDA’s pilot work on real-time clinical trials and the industry push for faster protocol changes. - More than three in four clinical trial protocols require a substantial amendment, and each amendment can take months and cost a median of more than $500,000 in a Phase III trial, according to the Tufts Center for the Study of Drug Development.

What happened: - Trialynx won DPHARM Idol Disrupt 2026 at the 16th annual DPHARM: Disruptive Innovations to Modernize Clinical Research conference in Boston. - A panel of 12 judges selected Trialynx from six finalists. - The judge panel included leaders from Gilead, Bristol Myers Squibb, Roche, Sanofi, Daiichi Sankyo, Summit Therapeutics, Bayer and AbbVie. - Ventsislav Dobrev, Global Clinical Integration Lead, Digital Biomarkers at Roche, said DPHARM’s official winner announcement that Trialynx can turn fragmented, document-based study design into an intelligent, structured digital workflow. - Angie Schwab, Trialynx founder and CEO, said the industry and the FDA are moving toward real-time clinical trials and that paper-based processes cannot support that shift.

The details: - Trialynx uses a hub-and-spoke model built around a single source of truth. - Study teams start with decisions, not documents, and evaluate market opportunities, regulatory requirements, budgets and timelines in one shared digital environment. - AI, automation and human review convert those decisions into more than 30 aligned study documents using each organization’s templates. - When a fact changes, including during a mid-study amendment, Trialynx updates the information once at the hub and pushes the change to every affected document and team. - Impact Explorer identifies what is affected and supports updates with a click and a full audit trail. - Trial information is captured in alignment with the Clinical Data Interchange Standards Consortium Unified Study Definitions Model and the International Council for Harmonisation M11 protocol standard. - Trialynx has supported 56 real-world evidence studies. - Across those studies, Trialynx cut the time to a first protocol draft by 94%, from an average of 18 days to about one day. - Trialynx also reduced revision cycles by 75%, from more than four rounds to one. - Ramesh Meesala, CEO of Cliniv, said working with Trialynx enabled the company to launch all of its trials weeks ahead of schedule.

Between the lines: - Trialynx is positioning its software as infrastructure for a broader move from static documents to connected digital trial operations. - The company’s emphasis on audit trails, standards alignment and change management suggests it is targeting the hardest part of trial modernization, not just document creation. - Schwab said the company created Zero to Digital in 90 Days to help teams test digital trials using their own studies, templates and workflows.

What's next: - Trialynx is directing sponsors and CROs to trialynx.io for more information. - The company will likely use the DPHARM win to expand adoption of its digital trial model among sponsors and CROs. - Trialynx is continuing to frame its platform as a foundation for real-time clinical trials.